Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Cancellation

27 Feb 2015 08:00

RNS Number : 0263G
Official List
27 February 2015
 



NOTICE OF CANCELLATION OF LISTING FROM THE OFFICIAL LIST

 

 

 

27/02/2015 8:00 AM

 

CANCELLATION

 

Ark Therapeutics Group Plc

 

The Financial Conduct Authority ("the FCA") cancels the securities set out below from the Official List effective from 27/02/2015 8:00 AM at the request of the company :

 

Ordinary Shares of 10p each

fully paid

Standard Shares 

(GB00BSZLMS59) ●

 

 

This notice has been issued by Listing Applications - 0207 066 8352.

 

Notes

 

- Notices issued by the FCA in respect of cancellation of securities from the Official List must be read in conjunction with notices issued by the relevant Recognised Investment Exchange.

 

● Denotes the security is also being cancelled from trading on the London Stock Exchange, a Recognised Investment Exchange.

- SEDOL numbers which are allocated by the London Stock Exchange as a Stock Exchange identifier may be found on their dealing notice.

 

† Denotes the security is also being cancelled from trading on ICAP Securities & Derivatives Exchange (ISDX), a Recognised Investment Exchange.

 

# Denotes the security is also being cancelled from trading on NYSE Euronext London, a Recognised Investment Exchange.

 

~ Denotes the security is also being cancelled from trading on BATS Europe Regulated Market, a Recognised Investment Exchange.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOTDQLFLELFZBBQ
Date   Source Headline
10th Mar 20101:21 pmRNSEPT Disclosure
10th Mar 201011:52 amRNSEPT Disclosure
10th Mar 20107:00 amRNSFinal Results
9th Mar 20107:00 amRNSResearch Update
8th Mar 20105:34 pmRNSHolding(s) in Company
23rd Feb 20107:00 amRNSResearch Update
19th Feb 20107:00 amRNSRe Agreement
16th Feb 20104:40 pmRNSSecond Price Monitoring Extn
16th Feb 20104:35 pmRNSPrice Monitoring Extension
11th Feb 201011:37 amRNSDirector/PDMR Shareholding
5th Feb 20104:35 pmRNSPrice Monitoring Extension
29th Jan 20103:23 pmRNSTotal Voting Rights
28th Jan 201011:05 amRNSNotice of Results
28th Jan 20107:02 amRNSResearch Update
28th Jan 20107:00 amRNSResearch Update
20th Jan 20103:51 pmRNSEmployee Benefit Trust
5th Jan 20107:00 amRNSArk files for re-examination of Cerepro
22nd Dec 20094:41 pmRNSSecond Price Monitoring Extn
22nd Dec 20094:35 pmRNSPrice Monitoring Extension
18th Dec 200911:56 amRNSEMEA recommendation on Cerepro
15th Dec 20092:29 pmRNSHolding(s) in Company
3rd Dec 20092:41 pmRNSBlocklisting Interim Review
3rd Dec 20092:35 pmRNSHolding(s) in Company
24th Nov 20094:04 pmRNSHolding(s) in Company
11th Nov 20097:00 amRNSInterim Management Statement
14th Oct 20097:00 amRNSResearch Update
2nd Oct 200911:04 amRNSHolding(s) in Company
30th Sep 200910:51 amRNSHolding(s) in Company
29th Sep 20094:32 pmRNSHolding(s) in Company
4th Sep 20097:00 amRNSResearch Update
1st Sep 200912:08 pmRNSDirector/PDMR Shareholding
26th Aug 20097:00 amRNSHalf Yearly Report
26th Aug 20097:00 amRNSResearch Update
13th Jul 20097:00 amRNSArk launches Kerraglove woundcare device
1st Jul 20097:00 amRNSRe Agreement
26th Jun 20092:15 pmRNSHolding(s) in Company
24th Jun 20097:00 amRNSManufacturing Update
17th Jun 20097:00 amRNSRe Agreement
3rd Jun 200911:47 amRNSBlocklisting Interim Review
21st May 20097:00 amRNSTrinam Phase III Study Enrols First Patient
18th May 20097:00 amRNSInterim Management Statement
15th May 20097:00 amRNSCerepro Named Patient Supply approved in Finland
13th May 20094:41 pmRNSSecond Price Monitoring Extn
13th May 20094:35 pmRNSPrice Monitoring Extension
12th May 20097:00 amRNSDirector/PDMR Shareholding
6th May 20094:40 pmRNSSecond Price Monitoring Extn
6th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20097:00 amRNSTrinam(R) Awarded Fast Track Status by FDA
30th Apr 20094:01 pmRNSTotal Voting Rights
30th Apr 200912:00 pmRNSPrestigious European Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.